167 related articles for article (PubMed ID: 3910223)
21. Optimal dosing with carboplatin.
Ozols RF
Semin Oncol; 1989 Apr; 16(2 Suppl 5):14-8. PubMed ID: 2655094
[TBL] [Abstract][Full Text] [Related]
22. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
23. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
24. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
25. [Development of carboplatin].
Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.
McGuire WP; Abeloff MD
J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458
[No Abstract] [Full Text] [Related]
28. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
Dittrich C; Sevelda P; Baur M; Marth C; Hudec M; Vavra N; Grunt T; Fazeny B; Salzer H
Cancer; 1993 May; 71(10):3082-90. PubMed ID: 8490836
[TBL] [Abstract][Full Text] [Related]
29. High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
Ozols RF; Ostchega Y; Myers CE; Young RC
J Clin Oncol; 1985 Sep; 3(9):1246-50. PubMed ID: 2993535
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin. The better platinum in head and neck cancer?
Volling P; Schröder M; Rauschning W; Achterrath W; Stennert E
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):695-8. PubMed ID: 2655667
[TBL] [Abstract][Full Text] [Related]
31. Carboplatin: the clinical spectrum to date.
Canetta R; Rozencweig M; Carter SK
Cancer Treat Rev; 1985 Sep; 12 Suppl A():125-36. PubMed ID: 3002623
[TBL] [Abstract][Full Text] [Related]
32. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
33. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer.
Rothenberg ML; Ostchega Y; Steinberg SM; Young RC; Hummel S; Ozols RF
J Natl Cancer Inst; 1988 Nov; 80(18):1488-92. PubMed ID: 2846858
[TBL] [Abstract][Full Text] [Related]
34. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity.
Dmitrovsky E; Seifter EJ; Gazdar AF; Tsai CM; Edison M; Brantley P; Veach SR; Batist G; Ihde DC; Mulshine JL
Am J Clin Oncol; 1990 Aug; 13(4):285-9. PubMed ID: 2165737
[TBL] [Abstract][Full Text] [Related]
37. [Phase III study of carboplatin in ovarian cancer].
Kato T; Nishimura H; Yamabe T; Terashima Y; Kasamatsu T; Hirabayashi K; Nishiya I; Yajima A; Takamizawa H; Tsutsui F
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2297-304. PubMed ID: 3044276
[TBL] [Abstract][Full Text] [Related]
38. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]